KPIs & Operating Metrics(New)
Growth Metrics

Bristol Myers Squibb (BMY) EBITDA Margin (2016 - 2026)

Bristol Myers Squibb has reported EBITDA Margin over the past 18 years, most recently at 24.65% for Q1 2026.

  • Quarterly EBITDA Margin rose 437.0% to 24.65% in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 15.12% through Mar 2026, up 379.0% year-over-year, with the annual reading at 14.04% for FY2025, 3193.0% up from the prior year.
  • EBITDA Margin was 24.65% for Q1 2026 at Bristol Myers Squibb, up from 8.6% in the prior quarter.
  • Over five years, EBITDA Margin peaked at 24.65% in Q1 2026 and troughed at 99.16% in Q1 2024.
  • The 5-year median for EBITDA Margin is 13.87% (2022), against an average of 7.77%.
  • Year-over-year, EBITDA Margin plummeted -11834bps in 2024 and then skyrocketed 11943bps in 2025.
  • A 5-year view of EBITDA Margin shows it stood at 13.87% in 2022, then fell by -6bps to 13.09% in 2023, then tumbled by -81bps to 2.45% in 2024, then surged by 251bps to 8.6% in 2025, then skyrocketed by 187bps to 24.65% in 2026.
  • Per Business Quant, the three most recent readings for BMY's EBITDA Margin are 24.65% (Q1 2026), 8.6% (Q4 2025), and 18.34% (Q3 2025).